Daniel Bolanowski
Analyst-Equity bij Arctic Asset Management AS (Sweden)
Profiel
Mr. Daniel Bolanowski is a Portfolio Manager at Arctic Asset Management AS.
He fills the role as an Analyst and has the responsibility of reaserch, value tracking.
valuation, opportunity sourcing.
He has more than 5 years of experience as business analyst and has had several engagements for small biotech/medtech companies.
Mr. Bolanowski worked as a Business Analyst at Karolinska Development AB, a Head-Business Development at Akinion Pharmaceuticals AB and Axelar AB.
He has a MSc in Biotechnology and a MSc in Business & Economics from the University of Uppsala.
Actieve functies van Daniel Bolanowski
| Bedrijven | Functie | Begin |
|---|---|---|
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Analyst-Equity | 01-01-2016 |
Eerdere bekende functies van Daniel Bolanowski
| Bedrijven | Functie | Einde |
|---|---|---|
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Private Equity Analist | 31-12-2015 |
| KAROLINSKA DEVELOPMENT AB | Corporate Officer/Principal | 01-12-2015 |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - |
Axelar AB
 Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KAROLINSKA DEVELOPMENT AB | Finance |
| Bedrijven in privébezit | 4 |
|---|---|
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Finance |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
Arctic Asset Management AS (Sweden)
Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Finance |
